Lateral Flow Assays Market Size, Share, Regional Growth, 2026-2034

Market OverviewAccording to fortune business insights, The global lateral flow assays market size was valued at USD 11.64 billion in 2025. The market is projected to grow from USD 12.53 billion in 2026 to USD 21.10 billion by 2034, exhibiting a CAGR of 6.7% during the forecast period. North America dominated the lateral flow assays market with a market share of 37.8% in 2025.The growing prevalence of chronic conditions such as infectious disorders, rapid disease screening, and the development of healthcare infrastructure are resulting in a growing penetration rate of these products. Additionally, the rising aging population and technological advancements by major players are fueling the adoption rate of lateral flow assays globally.

Major Players Profiled in the Market Report:• Abbott (U.S.)• Thermo Fisher Scientific Inc. (U.S.)• Hoffmann-La Roche Ltd. (Switzerland)• Siemens Healthineers AG (Germany)• QuidelOrtho Corporation (U.S.)• BIOMÉRIEUX (France)• JOYSBIO (Tianjin) Biotechnology Co., Ltd. (China)• Milenia Biotec GmbH (Germany)• Meizheng (China)• Danaher Corporation (U.S.)

SegmentsIncreasing Product Launches Led to Kits & Reagents Segment DominanceBased on product, the market is classified into LFA readers and kits & reagents. The kits & reagents segment held the largest revenue share in 2025. The growth is due to the growing prevalence of infectious disorders among patients, resulting in a rising number of diagnostic procedures globally, alongside the rising focus of key companies on launching novel kits.

Increasing Number of Diagnostic Procedures Led to Dominance of Sandwich Assays SegmentBased on technique, the market is segmented into sandwich assays, competitive assays, and multiplex detection assays. The sandwich assays segment dominated the global market with a share of 58.1% in 2025. This dominance is driven by the increasing number of diagnostic procedures and R&D activities to launch novel products using this technique.

Increasing Number of Hospitals & Clinics Led to Segmental DominanceBased on end user, the market is classified into hospitals & clinics, diagnostic laboratories, homecare settings, and others. The hospitals & clinics segment dominated the market in 2025, supported by the development of healthcare infrastructure and the increasing adoption of advanced products.

Report CoverageThe report offers:• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.• Comprehensive insights into regional developments.• List of major industry players.• Key strategies adopted by the market players.• The latest industry developments including technological advancements, new product launches, partnerships, mergers, and acquisitions.

Source: https://www.fortunebusinessinsights.com/lateral-flow-assays-market-115626

Drivers & RestraintsGrowing Burden of Infectious and Chronic Diseases to Boost Market GrowthThe growing burden of chronic and infectious disorders remains the prominent driver for the global market. Infectious disorders, including malaria, HIV, tuberculosis, and hepatitis, affect hundreds of millions of people every year. Additionally, the growing incidence of lifestyle-related chronic diseases, such as diabetes and cardiovascular diseases, has fueled the adoption of these products for routine check-ups and rapid triage.

However, the market faces restraints due to Limited Analytical Sensitivity Compared to Other Techniques. Lateral flow-based products generally offer reduced analytical sensitivity and specificity compared to laboratory-based techniques like molecular diagnostics (RT-PCR). This limitation increases concerns regarding false-negative results, particularly in early-stage disease detection or low-viral-load scenarios.

Regional InsightsNorth America Dominates Due to High Chronic PrevalenceNorth America held the dominant share in 2025, valued at USD 4.40 billion. The region’s growth is attributed to the growing prevalence of chronic conditions, developed hospital infrastructure, and strong adoption of OTC and point-of-care testing.

Asia Pacific to Witness Rapid GrowthAsia Pacific is estimated to be the second-largest region in the market, reaching USD 3.52 billion in 2026. Rapid testing programs and expanding healthcare access in developing economies like China and India are likely to support market growth.

Europe Market Supported by Established Regulatory FrameworkEurope is projected to record a growth rate of 4.7% in the coming years. The established regulatory framework and healthcare spending are likely to support the market, with key contributions from the U.K. and Germany.

Lateral Flow Assays Market Future Growth:A prominent trend shaping the market is the incorporation of digital workflow and smartphone-based analysis platforms to improve result accuracy and data management. Conventional visually interpreted lateral flow assays are increasingly being complemented by portable readers and digital immunoassay products that enhance sensitivity and clinical reliability. There is also an increasing demand for smartphone-enabled devices, particularly for home-based testing and remote patient monitoring, shifting the focus of key players toward R&D for novel, digitally integrated products.

Competitive LandscapeGrowing focus on R&D Activities by Major Players to Support their DominanceThe market features a robust and diversified product portfolio from major players like Abbott and Thermo Fisher Scientific, Inc. These companies are maintaining their dominance through a significant focus on strategic initiatives and R&D activities. Other key players, including F. Hoffmann-La Roche Ltd., are strengthening their presence through acquisitions and the launch of next-generation rapid antigen tests.

Key Industry Development• April 2024: QuidelOrtho Corporation received U.S. FDA 510(k) clearance for its QuickVue COVID-19 test.• August 2023: Anbio launched the Anbio LFA solution, an innovative diagnostic technique for detecting antigens such as viral proteins and cancer biomarkers.• July 2023: SEKISUI Diagnostics launched the OSOM COVID-19 Antigen Home Test.• July 2023: Hoffmann-La Roche Ltd. launched a combined SARS-CoV-2 and Influenza A/B rapid antigen test using lateral flow sandwich assay technology.